Business
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
- Topline results expected in the second half of 2022 -- Rosacea affects about 16 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / June 13, 2022 /
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- Topline results expected in the second half of 2022 -- Rosacea affects about 16 million patients in the U.S. -SAN DIEGO, CA / ACCESSWIRE / June 13, 2022 / Dermata Therapeutics, Inc. (\"Dermata,\" or the \"Company\") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea. DMT310 is Dermata's lead product candidate, consisting of a once-weekly topical treatment, utilizing both mechanical and chemical mechanisms of action. DMT310 is currently being investigated to treat multiple inflammatory skin conditions, including rosacea, acne, and psoriasis.\"Completing enrollment of the Phase 2 DMT310 rosacea study is a big step for us as we continue to develop DMT310 as an innovative treatment option for multiple inflammatory skin diseases,\" commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer. \"We believe that the similarities between rosacea and acne may lead to a similar reduction of inflammatory lesions in rosacea as we saw in our DMT310 Phase 2 acne trial, where acne patients treated with DMT310 experienced a 62% reduction in inflammatory lesions at week 12,\" continued Mr. Proehl. \"If DMT310 is approved for the treatment of moderate-to-severe rosacea, it could be the first once-weekly topical product to help treat the inflammatory lesions of rosacea. We look forward to announcing the topline results in the second half of 2022,\" concluded Mr. Proehl.DMT310-005 Phase 2 Trial DesignDMT310-005 is a 12-week, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate the efficacy, safety, and tolerability of once-weekly dosing of DMT310 in 180 moderate-to-severe rosacea patients. The primary endpoints include the mean change in inflammatory lesion counts (the number of papules and pustules on the face) and the Investigator's Global Assessment (IGA) of disease severity using a 5-point scale, with treatment success being defined as an IGA score of ‘clear' or ‘almost clear' and a 2-grade improvement from baseline at week 12.About DMT310DMT310 is Dermata's lead product candidate and incorporates the Company's proprietary Spongilla technology to topically treat a variety of der...